Fibrinolytic Therapy Market, By Drug Type, By Indication, By End User, By Administration (Intravenous, Intra-arterial ), By Distribution Channel, By Patient Age, By Packaging Type, By Application, By Dosage Form, By Region

Description

Global fibrinolytic therapy market is projected to reach US$ 45.08 Bn by 2030, from US$ 34.96 Bn in 2023, at a compound annual growth rate (CAGR) of 3.7% during 2023-2030.

Report Coverage		Report Details
Base Year:	2022	Market Size in 2023:	US$ 34.96 Bn
Historical Data for:	2018 to 2021	Forecast Period:	2023 - 2030
Forecast Period 2023 to 2030 CAGR:	3.70%	2030 Value Projection:	US$ 45.08 Bn

Figure 1. Global Fibrinolytic Therapy Market Share (%), By Region, 2023

Fibrinolytic therapy is used to dissolve blood clots that cause heart attacks or strokes. It is a lifesaving treatment, but it fails in underlying health problems that can lead to other serious diseases and conditions. Thrombolysis is usually given through an intravenous line. It is used when symptoms of a stroke or heart attack are present and the patient is not responding to other treatments, like anticoagulants and steroid medications. It can be given at home or in a hospital. Tissue plasminogen activator or alteplase is a drug that breaks down fibrin and other substances that create clots in the body that is most commonly used for thrombolysis. The drug tenecteplase is also effective in some patients, and it can also be given by mouth.

Market Dynamic:

The increasing incidences of trauma and road accidents are driving the demand for antifibrinolytic drugs, which in turn is fuelling fibrinolytic therapy market growth. The growing use of these drugs in oral bleeding treatments, mainly for menorrhagia (heavy menstrual flow) is again anticipated to bolster the market growth further. Moreover, rising incidences of severe road accidents and trauma is creating demand for anti-fibrinolytic drugs, thereby propelling the market growth. Furthermore, rising adoption of these drugs for treating hemophilia and other conditions such as platelet dysfunctions, Von Willebrand diseases and haemophilia A and B is further bolstering the market growth.

Also, the global fibrinolytic therapy market is driven by the rising prevalence of cardiovascular diseases, neurological disorders and pulmonary diseases causing blood clots. As per World Health Organization (WHO), cardiovascular diseases accounts for over 17.9 Mn deaths annually. Moreover, growing geriatric population prone to such diseases contributes to the market growth. However, high costs of fibrinolytic drugs, stringent regulations, and risk of bleeding associated with the therapy inhibits the market expansion. The market provides opportunities for development of effective recombinant variants, synthetic analogs, and hybrid molecules with greater specificity, enhanced fibrin specificity and reduced bleeding risks.

However, the high price of these drugs is a key factor that can hinder the market growth.

Key features of the study:

This report provides in-depth analysis of the global fibrinolytic therapy market, and provides market size (US$ Bn ) and compound annual growth rate (CAGR %) for the forecast period (2023-2030), considering 2022 as the base year
It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market
This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by key players
It profiles key players in the global fibrinolytic therapy market based on the following parameters - company highlights, products portfolio, key highlights, financial performance, and strategies
Key companies covered as a part of this study include Genentech, Inc. (Roche), Bayer AG, Boehringer Ingelheim International GmbH, Pfizer Inc., Bristol Myers Squibb Company, Novartis AG, AstraZeneca PLC, Johnson & Johnson, Daiichi Sankyo Company, Limited, Merck & Co., Inc., Sanofi S.A., Takeda Pharmaceutical Company Limited, Abbott Laboratories, Mallinckrodt Pharmaceuticals, and Mitsubishi Tanabe Pharma Corporation
Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics
Global fibrinolytic therapy market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global fibrinolytic therapy market

Detailed Segmentation:

Global Fibrinolytic Therapy Market, By Drug Type:
- Alteplase
- Reteplase
- Tenecteplase
- Streptokinase
- Anistreplase
- Urokinase
Global Fibrinolytic Therapy Market, By Indication:
- Acute Ischemic Stroke
- Acute Myocardial Infarction
- Deep Vein Thrombosis
- Peripheral Arterial Thrombosis
- Other Arterial Thrombosis
Global Fibrinolytic Therapy Market, By End User:
- Hospitals
- Ambulatory Surgical Centers
- Specialty Clinics
- Others
Global Fibrinolytic Therapy Market, By Administration:
- Intravenous (IV)
- Intra-arterial (IA)
Global Fibrinolytic Therapy Market, By Distribution Channel:
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
Global Fibrinolytic Therapy Market, By Patient Age:
- Adult Patients
- Pediatric Patients
Global Fibrinolytic Therapy Market, By Packaging Type:
- Vials
- Ampoules
- Pre-filled Syringes
Global Fibrinolytic Therapy Market, By Application:
- Emergency Care
- Interventional Cardiology
- Thrombosis Treatment
- Others
Global Fibrinolytic Therapy Market, By Dosage Form:
- Lyophilized Powder for Reconstitution
- Solution for Injection
Global Fibrinolytic Therapy Market, By Region:
- North America
- Europe
- Asia Pacific
- Latin America
- Middle East
- Africa
Top Companies in the Global Fibrinolytic Market:
- Genentech, Inc. (Roche)
- Bayer AG
- Boehringer Ingelheim International GmbH
- Pfizer Inc.
- Bristol Myers Squibb Company
- Novartis AG
- AstraZeneca PLC
- Johnson & Johnson
- Daiichi Sankyo Company, Limited
- Merck & Co., Inc.
- Sanofi S.A.
- Takeda Pharmaceutical Company Limited
- Abbott Laboratories
- Mallinckrodt Pharmaceuticals
- Mitsubishi Tanabe Pharma Corporation

Product Code: CMI5879

1. Research Objectives and Assumptions

Research Objectives
Assumptions
Abbreviations

2. Market Purview

Report Description
- Market Definition and Scope
Executive Summary
- Market Snippet, By Drug Type
- Market Snippet, By Indication
- Market Snippet, By End User
- Market Snippet, By Administration
- Market Snippet, By Distribution Channel
- Market Snippet, By Patient Age
- Market Snippet, By Packaging Type
- Market Snippet, By Application
- Market Snippet, By Dosage Form
- Market Snippet, By Region
Coherent Opportunity Map (COM)

3. Market Dynamics, Regulations, and Trends Analysis

Market Dynamics
- Driver
Increasing incidence of cardiovascular diseases
Growing geriatric population
Technological advancements
Access to healthcare facilities
- Restrain
Limited efficacy in certain patient populations
Risk of bleeding complications
Availability of alternative treatment modalities
Time sensitivity and door-to-needle delays
- Opportunities
Emerging markets
Combination therapies
Telemedicine and remote treatment
Personalized medicine
- Key Highlights
- Regulatory Scenario
- Recent Trends
- Product Launches/Approvals
- PEST Analysis
- PORTER's Analysis
- Mergers, Acquisitions, and Collaborations

4. Global Fibrinolytic Therapy Market - Impact of Coronavirus (COVID-19) Pandemic

COVID-19 Epidemiology
Supply Side and Demand Side Analysis
Economic Impact

5. Global Fibrinolytic Therapy Market, By Drug Type, 2018-2030, (US$ Bn)

Introduction
- Market Share Analysis, 2018 and 2030 (%)
- Y-o-Y Growth Analysis, 2019 - 2030
- Segment Trends
Alteplase
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2018-2030,(US$ Bn)
Reteplase
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2018-2030,(US$ Bn)
Tenacteplase
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2018-2030,(US$ Bn)
Streptokinase
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2018-2030,(US$ Bn)
Anistreplase
- Introduction
- Size and Forecast, and Y-o-Y Growth, 2018-2030,(US$ Bn)
Urokinase
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2018-2030,(US$ Bn)

6. Global Fibrinolytic Therapy Market, By Indication, 2018-2030, (US$ Bn)

Introduction
- Market Share Analysis, 2018 and 2030 (%)
- Y-o-Y Growth Analysis, 2019 - 2030
- Segment Trends
Acute Ischemic Stroke
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2018-2030,(US$ Bn)
Acute Myocardial Infarction
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2018-2030,(US$ Bn)
Deep Vein Thrombosis
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2018-2030,(US$ Bn)
Peripheral Arterial Thrombosis
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2018-2030,(US$ Bn)
Other Arterial Thrombosis
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2018-2030,US$ Bn(US$ Bn)

7. Global Fibrinolytic Therapy Market, By End User, 2018-2030, (US$ Bn)

Introduction
- Market Share Analysis, 2018 and 2030 (%)
- Y-o-Y Growth Analysis, 2019 - 2030
- Segment Trends
Hospitals
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2018-2030,(US$ Bn)
Ambulatory Surgical Centers
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2018-2030,(US$ Bn)
Speciality Clinics
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2018-2030,(US$ Bn)
Others
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2018-2030,(US$ Bn)

8. Global Fibrinolytic Therapy Market, By Administration, 2018-2030, (US$ Bn)

Introduction
- Market Share Analysis, 2018 and 2030 (%)
- Y-o-Y Growth Analysis, 2019 - 2030
- Segment Trends
Intravenous (IV)
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2018-2030,(US$ Bn)
Intra-arterial (IA)
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2018-2030,(US$ Bn)

9. Global Fibrinolytic Therapy Market, By Distribution Channel, 2018-2030, (US$ Bn)

Introduction
- Market Share Analysis, 2018 and 2030 (%)
- Y-o-Y Growth Analysis, 2019 - 2030
- Segment Trends
Hospital Pharmacies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2018-2030,(US$ Bn)
Retail Pharmacies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2018-2030,(US$ Bn)
Online Pharmacies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2018-2030,(US$ Bn)

10. Global Fibrinolytic Therapy Market, By Patient Age, 2018-2030, (US$ Bn)

Introduction
- Market Share Analysis, 2018 and 2030 (%)
- Y-o-Y Growth Analysis, 2019 - 2030
- Segment Trends
Adult Patients
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2018-2030,(US$ Bn)
Pediatric Patients

11. Global Fibrinolytic Therapy Market, By Packaging Types, 2018-2030, (US$ Bn)

Introduction
- Market Share Analysis, 2018 and 2030 (%)
- Y-o-Y Growth Analysis, 2019 - 2030
- Segment Trends
Vials
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2018-2030,(US$ Bn)
Ampoules
Pre-filled Syringes

12. Global Fibrinolytic Therapy Market, By Application, 2018-2030, (US$ Bn)

Introduction
- Market Share Analysis, 2018 and 2030 (%)
- Y-o-Y Growth Analysis, 2019 - 2030
- Segment Trends
Emergency Care
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2018-2030,(US$ Bn)
Interventional Cardiology
Thrombosis Treatment
Others

13. Global Fibrinolytic Therapy Market, By Dosage Form, 2018-2030, (US$ Bn)

Introduction
- Market Share Analysis, 2018 and 2030 (%)
- Y-o-Y Growth Analysis, 2019 - 2030
- Segment Trends
Lyophilized Powder for Reconstitution
Solution for Injection

14. Global Fibrinolytic Therapy Market , By Region, 2018-2030, (US$ Bn)

Introduction
- Market Share Analysis, By Region, 2018 and 2030 (%)
- Y-o-Y Growth Analysis, For Region, 2018 -2030
- Country Trends
North America
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Drug Type, 2018-2030,(US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Indication, 2018-2030,(US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By End User, 2018-2030,(US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Administration, 2018-2030,(US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2018-2030,(US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Patient Age, 2018-2030,(US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Packaging Type, 2018-2030,(US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Application, 2018-2030,(US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Dosage Form, 2018-2030,(US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2018-2030,(US$ Bn)
U.S.
Canada
Europe
Germany
U.K.
France
Italy
Spain
Russia
Rest of Europe
Asia Pacific
China
India
Japan
Australia
South Korea
ASEAN
Rest of Asia Pacific
Latin America
Brazil
Mexico
Argentina
Rest of Latin America
Middle East
GCC Countries
Israel
Rest of Middle East
Africa
South Africa
Central Africa
North Africa

15. Competitive Landscape

Company Profile
- Genentech, Inc. (Roche)
Company Highlights
Product Portfolio
Key Developments
Financial Performance
Strategies
- Bayer AG
- Boehringer Ingelheim International GmbH
- Pfizer Inc.
- Bristol Myers Squibb Company
- Novarts AG
- AstraZeneca PLC
- Johnson & Johnson
- Daiichi Sankyo Company, Limited
- Merck & Co., Inc.
- Sanofi S.A.
- Takeda Pharmaceutical Company Limited
- Abbott Laboratories
- Mallinckrodt Pharmaceuticals
- Mitsubishi Tanabe Pharma Corporation
Analyst Views

16. Section

References
Research Methodology
About us